Erkut Borazanci, MD
Medical Oncology · Scottsdale, AZNPI 1992972384
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,743 of the $31,235 with a category attached, or 72.8%. 7 manufacturers reported payments, led by Corcept Therapeutics at 57.3% of the total. 2025 is the largest year on record at $21,100, 6.0 times the $3,492 reported in 2019.
Across 31 payments — averaging $1007.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$18K
- Ipsen Biopharmaceuticals, Inc$7K
- Partner Therapeutics, Inc.$4K
- Taiho Oncology, Inc.$2K
- Merck$115
- Boston Scientific$94
- plus $22 from 1 others
Across 175 payments — averaging $19,628 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.7M
- Jazz Pharmaceuticals Inc.$484K
- Corcept Therapeutics$333K
- Biontech SE$251K
- E.r. Squibb & Sons, L.L.C.$229K
- Merck$181K
- plus $293K from 3 others
What the payments were for
- Consulting fees$6,01519%
- Speaking & faculty fees$22,74373%
- Travel & lodging$1,6025%
- Food & beverage$8753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 12 | $17,897 |
| Ipsen Biopharmaceuticals, Inc | 5 | $6,761 |
| Partner Therapeutics, Inc. | 10 | $4,006 |
| Taiho Oncology, Inc. | 1 | $2,340 |
| Merck | 1 | $115 |
| Boston Scientific | 1 | $94 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONIVYDE$6,733
- Korlym$3,148
- Bizengri$3,000
- Lonsurf$2,340
- SOMATULINE DEPOT$1,550
How this compares
$31,235 in reported general payments places this provider in the 80th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 21 | $42,837 |
| Enoxaparin Sodium | 20 | $5,554 |
| Dexamethasone | 23 | $396 |
| Ondansetron OdtOndansetron | 26 | $356 |
| Oxycodone Hcl | 17 | $313 |
| Olanzapine | 12 | $264 |
| Potassium Chloride | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Scottsdale
- Daniel von HoffScottsdale$165K
- Rajinder GroverScottsdale$13K
- Rishi AgarwalScottsdale$12K
- Walter KimScottsdale$6K
- Ashish ChintakuntlawarScottsdale$2K
- John BibbScottsdale$713
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.